JPRN-UMIN000011099招募中2 期
DAsatinib DIscontinuation for 1st-Line treatment with Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission - 1st DADI-Trial
1st DADI/IMIDAS4th -Trial Group0 个研究点目标入组 100 人开始时间: 2013年7月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who have been treated by TKI except Dasatinib or Interferon.(except patients who have treated by Imatinib within 4 weeks as an ex-treatment.) 2. Concurrent malignancy other than CML 3.Women who are pregnant or breastfeeding 4.A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy
研究者
相似试验
Unknown
2 期
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS TrialMyelogenous Leukemia, Chronic, Chronic PhaseNCT01887561Kanto CML Study Group100
进行中（未招募）
1 期
Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial. - SAKK 56/07EUCTR2007-002047-24-DESwiss Group for Clinical Cancer Reaserch (SAKK)52
进行中（未招募）
不适用
Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial. - SAKK 56/07 (DaFLiG)GIST (Gastrointestinal stromal tumor) is a rare disease affecting 15 patients per 1 million individuals and comprising 5% of all sarcomas. Mutations in the genes of KIT or PDGFRA lead to constitutive activation of the encoded receptor and are the pathogenetic reason for the development of clinical GIST. GIST is a potentially curable disease, if complete resection of localized tumor is possible. Inoperable GIST cannot be cured at present.MedDRA version: 9.1Level: LLTClassification code 10051066Term: Gastrointestinal stromal tumourEUCTR2007-002047-24-FRSwiss Group for Clinical Cancer Reaserch (SAKK)52
进行中（未招募）
1 期
Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutatioCarcinoma, Non-small cell lungMedDRA version: 14.1 Level: LLT Classification code 10007284 Term: Carcinoma System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864EUCTR2011-003128-11-GBBristol-Myers Squibb International Corporation19
进行中（未招募）
不适用
Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutatioCarcinoma, Non-small cell lungMedDRA version: 14.1Level: LLTClassification code 10007284Term: CarcinomaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2011-003128-11-DEBristol-Myers Squibb International Corporation73